Last reviewed · How we verify
GLP-1 RAs
GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels.
GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels. Used for Type 2 diabetes mellitus, Obesity or weight management (in some formulations).
At a glance
| Generic name | GLP-1 RAs |
|---|---|
| Also known as | Dulaglutide |
| Sponsor | Shanghai 10th People's Hospital |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
GLP-1 RAs bind to and activate GLP-1 receptors on pancreatic beta cells, which stimulates glucose-dependent insulin secretion. They simultaneously inhibit glucagon secretion from alpha cells and delay gastric emptying, all of which contribute to improved glycemic control. Additionally, GLP-1 RAs promote satiety and have been shown to reduce body weight and provide cardiovascular benefits in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management (in some formulations)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Key clinical trials
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs (NA)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists (NA)
- Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) (PHASE1)
- A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 RAs CI brief — competitive landscape report
- GLP-1 RAs updates RSS · CI watch RSS
- Shanghai 10th People's Hospital portfolio CI